Clinical trials: Arthritis,Rheumatoid
Rheumatoid Arthritis
Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)
The primary objective of this study is to evaluate the efficacy of atacicept compared to placebo in the treatment of signs and symptoms in a subject population with active rheumatoid arthritis (RA), inadequate response to…
- Trial name
- AUGUST II (NCT00595413)
- Testing
- Atacicept: with loading dose, Atacicept, Adalimumab
- Where
- 2 sites in United States, Germany
- Volunteers
- 311 people
- Sponsor
- EMD Serono
Rheumatoid Arthritis
Comparative Pharmacokinetic Trial of RGB-03 and MabThera
Pharmacokinetic properties, efficacy, safety and tolerability of RGB-03 and MabThera will be compared in patients suffering from Rheumatoid Arthritis.
- Trial name
- NCT02371096
- Testing
- MabThera (rituximab), RGB-03
- Sponsor
- Gedeon Richter Plc.
Rheumatoid Arthritis
CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis
This trial will test the hypothesis that the administration of CF101, a novel anti-inflammatory agent, to patients with rheumatoid arthritis will relieve signs and symptoms of the disease.
- Trial name
- NCT02647762
- Testing
- CF101 1 mg, CF101 2 mg, MTX
- Where
- 35 sites in Bosnia and Herzegovina, Canada and 5 more
- Volunteers
- 244 people
- Sponsor
- Can-Fite BioPharma
Rheumatoid Arthritis
Combination Therapy of F8IL10 and Methotrexate in Rheumatoid Arthritis Patients
Phase I, multicenter, open-label, dose escalation study to test the efficacy and safety of F8IL10 and methotrexate when given as a combination in rheumatoid arthritis patients.
- Trial name
- NCT02076659
- Testing
- F8IL10, Methotrexate
- Where
- 5 sites in Italy
- Volunteers
- 36 people
- Sponsor
- Philogen S.p.A.
Arthritis, Rheumatoid
Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403
A 3-year open-label trial for patients who previously participated in Trial Hx-CD20-403 and who fulfill the eligibility criteria for this trial (GEN413) .
- Trial name
- NCT00655824
- Testing
- ofatumumab
- Where
- 10 sites in United States, Denmark and 3 more
- Volunteers
- 124 people
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MTRX1011A in Patients With Rheumatoid Arthritis
This is a Phase I multicenter study that will be conducted in the United States and consists of a double-blind, placebo-controlled, SAD stage, followed by a double-blind, placebo controlled MAD stage.
- Trial name
- NCT00718588
- Testing
- MTRX1011A
- Volunteers
- 66 people
- Sponsor
- Genentech, Inc.
Knee Osteoarthritis, Rheumatoid Arthritis
Freedom® Total Knee System for Treatment of Osteoarthritis, Rheumatoid Arthritis or Post-traumatic Arthritis
A prospective, multi-centre, non-comparative, post-market clinical follow-up study to evaluate the survivorship, safety and performance of the Freedom® Total Knee System in the treatment of approximately 450 subjects who in the…
- Conditions
- Knee Osteoarthritis, Rheumatoid Arthritis, Post-traumatic Osteoarthritis
- Trial name
- Freedom®450 (NCT04033588)
- Testing
- Freedom® Total Knee System
- Volunteers
- 450 people
- Sponsor
- Meril Life Sciences Pvt. Ltd.
Rheumatoid Arthritis
EMBRACE-SC: Observational Study of Subcutaneous (SC) Tocilizumab Alone or in Combination With Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) in Rheumatoid Arthritis
The purpose of this study is to evaluate the percentage of participants treated with subcutaneous (SC) Tocilizumab who are still on treatment after 52 weeks and the factors that play a major role in continuation of treatment.
- Trial name
- NCT02648035
- Testing
- Tocilizumab
- Where
- 26 sites in Greece
- Volunteers
- 200 people
- Sponsor
- Hoffmann-La Roche
Inflammation, Rheumatoid Arthritis
Safety and Tolerability of NNC0114-0006 at Increasing Dose Levels in Subjects With Rheumatoid Arthritis
This trial is conducted in Europe. The aim of this dose-escalating trial is to assess the safety and tolerability of multiple doses of NNC0114-0006 in subjects with rheumatoid arthritis (RA).
- Trial name
- NCT01565408
- Testing
- NNC0114-0006
- Where
- 5 sites in Germany, Russia
- Volunteers
- 32 people
- Sponsor
- Novo Nordisk A/S
Rheumatoid Arthritis
Study Evaluating Single Doses Of SBI-087 in Subjects With Rheumatoid Arthritis
The purpose of this study is to determine the safety and tolerability of single doses of SBI-087 in subjects with rheumatoid arthritis.
- Trial name
- NCT00641225
- Testing
- SBI-087
- Where
- 6 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trial 016.0012
This is an open label, multicenter study for extended treatment of patients who have participated in the Immunex clinical study 016.0012.
- Trial name
- NCT00356590
- Testing
- Etanercept
- Volunteers
- 468 people
- Sponsor
- Amgen
Rheumatoid Arthritis
Effect of Patient Cost Sharing on Treatment Discontinuation Among Rheumatoid Arthritis Patients
The purpose of this study is to assess the impact of patient cost sharing on treatment discontinuation of biologic agents in patients with Rheumatoid Arthritis (RA)
- Trial name
- NCT01137851
- Volunteers
- 3,940 people
- Sponsor
- Bristol-Myers Squibb
Arthritis, Psoriatic, Arthritis, Rheumatoid
Study Evaluating Etanercept in Patients With Rheumatoid Arthritis(RA), Juvenile Idiopathic Arthritis (JIA), or Psoriatic Arthritis (PsA) in Spain
The purpose of this study is to assess the safety of etanercept in patients with rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) or psoriatic arthritis (PsA) in Spain
- Trial name
- NCT00195377
- Testing
- Etanercept
- Where
- Spain
- Volunteers
- 1,000 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Rheumatoid Arthritis
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
The core and extension studies assessed the safety and efficacy of secukinumab when added to a background therapy in patients with active rheumatoid arthritis who are intolerant to or have had an inadequate response to anti-TNF-α…
- Trial name
- REASSURE (NCT01377012)
- Testing
- Secukinumab (AIN457)
- Where
- 142 sites in United States, Argentina and 14 more
- Volunteers
- 637 people
- Sponsor
- Novartis Pharmaceuticals
Arthritis, Rheumatoid
A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)
The purpose of this study is to evaluate the safety and efficacy of 3 different doses of belimumab, administered in addition to standard therapy, in patients with rheumatoid arthritis (RA).
- Trial name
- NCT00071812
- Testing
- Belimumab 1 mg/kg, Belimumab 4 mg/kg, Belimumab 10 mg/kg
- Where
- 63 sites in United States
- Volunteers
- 283 people
- Sponsor
- Human Genome Sciences Inc.
Rheumatoid Arthritis
A Study of Tocilizumab + DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis
This single arm study will assess the effect of tocilizumab + DMARDs (Disease Modifying Anti-Rheumatic Drugs)on improvement of anemia and fatigue in patients with moderate to severe active rheumatoid arthritis.
- Trial name
- NCT00951275
- Testing
- tocilizumab [RoActemra/Actemra], Standard DMARDs (Disease Modifying Anti Rheumatic Drugs)
- Where
- 27 sites in Italy
- Volunteers
- 105 people
- Sponsor
- Hoffmann-La Roche
Sjogren Syndrome
Intra-Nasal Mechanical Stimulation (INMEST) as a Potential Treatment Method for Sjogren's Syndrome (SS)
The purpose of the study is to investigate the effect and safety of the Walther System delivering INMEST (intranasal mechanical stimulation) on people with Sjogren\'s syndrome.
- Trial name
- A-SS-001 (NCT06626477)
- Testing
- Intra nasal mechanical stimulation treatment (INMEST)
- Where
- Sweden
- Volunteers
- 26 people
- Sponsor
- Abilion Medical Systems AB
Rheumatoid Arthritis
A Study of MabThera/Rituxan (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis and Inadequate Response to DMARD Therapy
This study will evaluate the efficacy and safety of MabThera/Rituxan plus methotrexate in patients with active rheumatoid arthritis who have had an inadequate response to at least 1 DMARD treatment.
- Trial name
- NCT02006706
- Testing
- rituximab [MabThera/Rituxan], methotrexate, methylprednisolone
- Where
- 3 sites in Serbia
- Volunteers
- 15 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis
A phase 2a open-label study to evaluate the long-term safety and efficacy of ABX464 50mg as maintenance therapy in patients with moderate to severe rheumatoid arthritis.
- Trial name
- NCT04049448
- Testing
- ABX464
- Where
- 14 sites in Belgium, France and 2 more
- Volunteers
- 40 people
- Sponsor
- Abivax S.A.
Healthy
Pharmacokinetics And Tolerability Of Subcutaneous Administration Of PF 04236921 In Healthy Volunteers
This study will evaluate the safety, tolerability, and pharmacokinetics of PF-04236921 administered as a single subcutaneous dose in healthy volunteers.
- Trial name
- NCT01166555
- Testing
- PF-04236921
- Where
- Belgium
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.